Pharma companies directory 2026

    Pharmaceutical Companies in Poland

    Poland is the biggest medicines market in Central and Eastern Europe, and the competitive story is still written by domestic generic houses rather than by a handful of Western originators.

    Statistics Poland put prescription turnover at PLN 33.4 billion in 2025, while IQVIA’s pharmacy audit for the same year counted PLN 60.6 billion once consumer-health lines are added. Narodowy Fundusz Zdrowia now finances 45.9% of that prescription bill, up from well under two fifths only three years earlier, so a brand’s fate is decided on the reimbursement list and in hospital drug programmes long before a medical representative walks into a clinic. URPL remains the national competent authority beside the EMA, AOTMiT writes the HTA opinions the Ministry of Health uses to price and list, and hospital buyers run their own tenders on top of the outpatient list. Polpharma, Adamed, Polfa Tarchomin, Celon Pharma and Biomed Lublin give the country a manufacturing base that also ships into neighbouring CEE markets; Krka, Gedeon Richter and the usual Swiss and US affiliates sit beside them. BioNixus uses the roster below when a client needs to know who actually wins volume on an NFZ list, who shows up at a wojewódzki hospital tender, and which plant can support a licensed launch.

    Updated September 2026 · Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) — authorised medicines and licensed manufacturers as of September 2026 · 18 named accounts

    Request a proposal for PolandBrowse the 18 companies

    PLN 60.6bn

    Total pharmacy market (Rx plus consumer health) in 2025, IQVIA / PASMI

    PLN 33.4bn

    Prescription-medicine sales in 2025, Statistics Poland

    45.9%

    NFZ share of prescription value in 2025, up from 39.3% in 2022

    515.6m

    Prescriptions dispensed in 2025, almost all of them electronic

    Named accounts

    Top pharmaceutical companies in Poland

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) — authorised medicines and licensed manufacturers (as of 2026-09-04).
    #CompanyHQ
    01PolpharmaStarogard Gdański
    02AdamedPieńków
    03Polfa TarchominWarsaw
    04Biomed LublinLublin
    05Celon PharmaKiełpin
    06Krka PolskaWarsaw
    07Gedeon Richter PolskaWarsaw
    08Teva Pharmaceuticals PolskaWarsaw
    09Pfizer PolskaWarsaw
    10Novartis PolandWarsaw
    11Roche PolskaWarsaw
    12Polpharma BiologicsGdańsk
    13Aflofarm Farmacja PolskaPabianice
    14Hasco-LekWrocław
    15Office for Registration of Medicinal Products (URPL)Warsaw
    16Narodowy Fundusz Zdrowia (NFZ)Warsaw
    17AOTMiTWarsaw
    18NeucaToruń

    Primary research

    These are the pharmaceutical companies accounts we study in Poland

    Need account-level or SKU-level data for a brand in Poland? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Poland?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top healthcare market research companies in Poland (2026)

    How the market is structured

    Reimbursement lists, hospital programmes and the pharmacy shelf in Poland

    A medicine that will be sold in Poland needs either an EMA centralised authorisation or a national / DCP file at URPL, after which commercial work splits. Outpatient products that want public money enter the reimbursement procedure: AOTMiT assesses clinical and economic evidence, the Ministry of Health negotiates price and limit groups, and the product appears on a list that NFZ refreshes every two months. Patients still pay a co-payment, and that residual is large enough that pharmacy substitution and limit-group clustering matter as much as the headline reimbursement decision. Hospital oncology and other high-cost therapies travel a second path, the B-programmes, where inclusion is a separate negotiation and volume then depends on contracts with individual szpitale kliniczne and regional networks. Wholesalers such as Neuca move stock to more than ten thousand community pharmacies; chains and independent apteki both exist, but neither looks like a Western banner market. Export is part of the industrial model: Polpharma and Adamed treat Czech, Slovak, Hungarian, Romanian and Ukrainian registrations as a second home market, which is why plant audits and CEE launch sequencing sit on the same brief as Warsaw access work.

    Local

    Polish-owned manufacturers, from Polpharma’s CEE platform to Celon’s pipeline and Aflofarm’s consumer brands, that still take the larger share of pharmacy packs and many hospital lots.

    • Polpharma
    • Adamed
    • Polfa Tarchomin
    • Biomed Lublin
    • Celon Pharma
    • Polpharma Biologics
    • Aflofarm Farmacja Polska
    • Hasco-Lek

    Multinational

    Originator affiliates whose Polish business is now specialty, vaccines and hospital programmes rather than primary-care blockbusters, plus Teva competing on generic price.

    • Teva Pharmaceuticals Polska
    • Pfizer Polska
    • Novartis Poland
    • Roche Polska

    Regional

    CEE neighbours — Krka from Slovenia and Gedeon Richter from Hungary — that treat Poland as a core branded-generic market rather than a satellite.

    • Krka Polska
    • Gedeon Richter Polska

    Distributors & importers

    URPL, AOTMiT and NFZ on the public side, and Neuca on the wholesale side: the institutions that decide whether a registered product is actually paid for and stocked.

    • Office for Registration of Medicinal Products (URPL)
    • Narodowy Fundusz Zdrowia (NFZ)
    • AOTMiT
    • Neuca

    Market structure

    How AOTMiT, the Ministry and NFZ actually sequence a listing

    Teams used to Western HTA often underestimate the two-month list rhythm and the limit-group arithmetic. AOTMiT does not publish a statutory cost-per-QALY cap, yet reviewers still work with a long-standing multiple of GDP per capita, and oncology files face a tighter practical ceiling because NFZ budgets are already stretched. After a positive opinion the Ministry clusters products into limit groups, which is why a late generic can collapse the reimbursed price of a whole class overnight.

    Hospital programmes sit outside that outpatient machine. A molecule can be reimbursed in a B-programme while remaining invisible in community pharmacies, and voivodeship contractors then decide real volume. That is the reason BioNixus splits Polish access work into a list-and-limit workstream and a separate hospital-tender workstream instead of treating “reimbursement” as one question.

    What is moving

    What is moving the pharmaceutical market in Poland

    NFZ reimbursement deepening

    Public money now covers close to half of prescription value, and the 2022–2025 jump in NFZ outlays is faster than patient co-payments, so list placement and limit-group strategy decide growth more than detailing volume.

    Hospital B-programmes and oncology spend

    High-cost therapies are carved into named drug programmes; Roche, Pfizer, Novartis and a few domestic injectables suppliers live or die on those contracts rather than on pharmacy audits.

    CEE export as a second P&L

    Polpharma’s stated aim to double non-Polish CEE sales, together with Adamed and Hasco shipments, turns plant capacity and neighbouring registrations into a competitive variable inside Poland itself.

    Domestic biosimilars and respiratory innovation

    Polpharma Biologics and Celon’s pipeline give Polish capital a route into specialty that used to belong only to affiliates, which changes who a payer can play off against an originator.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Poland

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Poland:
    • NFZ list and limit-group reconstructions for cardiometabolic and respiratory classes, tracking how a new generic resets the reimbursed price across a cluster.
    • Hospital-programme interviews with pharmacists and purchase committees in Warsaw and Kraków teaching hospitals on B-programme uptake and tender award prices.
    • AOTMiT evidence-gap workshops with local HEOR consultants before an innovative filing, focused on Polish EQ-5D assumptions and budget-impact framing.
    • Pharmacy purchase-record audits in Warsaw and Kraków comparing Polpharma, Adamed, Krka and originator share inside the same INN.

    Questions

    Frequently Asked Questions

    Who are the main pharmaceutical manufacturers headquartered in Poland?

    Polpharma, Adamed, Polfa Tarchomin, Celon Pharma, Biomed Lublin, Aflofarm and Hasco-Lek are the names that recur on URPL manufacturing licences and on NFZ outpatient or hospital awards. Polpharma remains the largest by domestic sales, but its 2025 share was still under 6%, which shows how fragmented the rest of the field is.

    How does NFZ reimbursement work for a new medicine?

    After URPL or EMA authorisation, the company files for reimbursement. AOTMiT issues an HTA opinion, the Ministry of Health negotiates price and limit-group placement, and NFZ then pays according to the published list, which is typically refreshed every two months. Hospital B-programmes are a separate track.

    Do hospital tenders matter as much as the pharmacy channel?

    For oncology, biologics, sterile injectables and vaccines, yes. Community pharmacies still dominate pack volume, but a growing share of value sits in programmes and szpital purchases that never appear in a retail audit.

    Is Poland used as a launch pad for other CEE countries?

    Often. Domestic groups already sell into Czechia, Slovakia, Hungary, Romania and Ukraine, and several multinationals run CEE medical and access teams from Warsaw. Dossier reuse is real, but each payer still has its own HTA and tender rules.

    How does BioNixus research pharmaceutical companies in Poland?

    By interviewing hospital pharmacists and programme coordinators in Warsaw and Kraków, reconstructing NFZ list and limit-group changes by molecule, sitting with AOTMiT-experienced consultants on HTA evidence gaps, and auditing pharmacy purchase records for branded-generic share in cardiometabolic and respiratory baskets.

    Does the order of companies on this page reflect Polish market share?

    No. Names sit here because they keep turning up in URPL filings, NFZ reimbursement lists and BioNixus hospital-tender work. Row order is editorial, not a sales league.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Poland. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) — authorised medicines and licensed manufacturers, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Poland, not size.

    • Statistics Poland, Sales of prescription medicines in 2025; NFZ reimbursement share 45.9%
    • IQVIA / PASMI, Rynek Farmaceutyczny w Polsce w roku 2025 — PLN 60.6bn pharmacy market
    • Polpharma CEE strategy coverage and 2025 share commentary; WSE filings for Celon Pharma and Biomed Lublin
    • BioNixus Poland NFZ-list, hospital-programme and pharmacy fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Poland?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Poland?

    Primary research, market access & HEOR. Proposals within 48 hours.